Physician profile
Alan S David
NPI 1740240613
$729.75
in general payments reported to CMS, 2019-2025
12 companies · $458 in 2025
The $458 reported for 2025 was more than what 79% of Neuromusculoskeletal Medicine & Omm providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.30 · 2022: $49.40 · 2023: $19.79 · 2024: $189 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $667.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $300.27 | 2024-2025 | |
| Boston Scientific Corporation | $81.48 | 2024 | |
| Biogen, INC. | $63.79 | 2024-2025 | Leqembi |
| Pfizer INC. | $62.52 | 2024-2025 | |
| Amgen INC. | $46.15 | 2025 | Uplizna |
| Abbvie INC. | $46.10 | 2025 | |
| Neurocrine Biosciences, INC. | $27.56 | 2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $26.91 | 2022 | |
| Avion Pharmaceuticals | $22.49 | 2022 | |
| Nevro Corp. | $19.79 | 2023 | Senza |
| Sk Life Science, INC. | $19.39 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan David listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.